Use of Daratumumab in Patients With Previously Treated Multiple Myeloma

被引：0
|
作者：
Patel, Ashwin P. [1 ]
机构：
[1] Emory Univ, Sch Med, Atlanta, GA 30322 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 14期
关键词：
D O I：
10.1200/JCO.22.02850
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Daratumumab, Bortezomib, and Dexamethasone for Previously Treated Multiple Myeloma
    Huang, Shang-Xiao
    Luo, Peng-Hui
    Wang, Han-Lei
    Mo, Dun-Chang
    Huang, Jian-Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2667 - 2668
  • [2] NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
    Elsada, Ahmed
    Adler, Amanda I.
    LANCET ONCOLOGY, 2019, 20 (05): : 619 - 620
  • [3] Daratumumab, Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naive Relapsed Refractory Multiple Myeloma Patients
    Ouchveridze, Evguenia
    Singh, Chandandeep
    Atrash, Shebli
    Paul, Barry
    Mohan, Meera
    Alkharabsheh, Omar
    Afrough, Aimaz
    Cui, Wei
    Mahmoudjafari, Zahra
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2022, 140 : 7164 - 7165
  • [4] Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab: Darazadex
    Kambhampati, Swetha
    Wong, Sandy W.
    Martin, Thomas, III
    Wolf, Jeffrey L.
    Choudhry, Priya
    Karlon, William
    Wiita, Arun P.
    Shah, Nina
    BLOOD, 2020, 136
  • [5] Use of a Cord Blood Panel for Daratumumab Treated Multiple Myeloma Patients in a Clinical Setting
    Barry, Maria
    Armstrong, Braden
    TRANSFUSION, 2017, 57 : 161A - 162A
  • [6] STUDY OF INFECTIOUS COMPLICATIONS IN MULTIPLE MYELOMA PATIENTS TREATED WITH DARATUMUMAB
    Diaz, Galvez Francisco J.
    Barrigon Fernando, Escalante
    Vals Julio, Davila
    Saavedra Veronica, Campuzano
    Gomez Jorge, Labrador
    Garcia Abelardo, Barez
    Maria Del Carmen, Hermoso Martinez
    Nuno Rodolfo, Alvarez
    HAEMATOLOGICA, 2021, 106 (10) : 140 - 141
  • [7] Risk of RBC alloimmunization in multiple myeloma patients treated by Daratumumab
    Ye, Zhan
    Wolf, Laurie A.
    Mettman, Daniel
    Plapp, Fred, V
    VOX SANGUINIS, 2020, 115 (02) : 207 - 212
  • [8] Risk of RBC Alloimmunization in Multiple Myeloma Patients Treated by Daratumumab
    Ye, Zhan
    Wolf, Laurie
    Plapp, Fred
    TRANSFUSION, 2018, 58 : 188A - 188A
  • [9] Subcutaneous daratumumab in patients with multiple myeloma who have been previously treated with intravenous daratumumab: A multicenter, randomized, phase II study (LYNX).
    Bahlis, Nizar J.
    Zonder, Jeffrey A.
    Wroblewski, Susan
    Qi, Ming
    Renaud, Thomas
    Jackson, Carolyn Chang
    Facon, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Selinexor for the treatment of patients with previously treated multiple myeloma
    Mo, Clifton C.
    Jagannath, Sundar
    Chari, Ajai
    Nooka, Ajay K.
    Lonial, Sagar
    Siegel, David
    Biran, Noa
    Gasparetto, Cristina
    Bahlis, Nizar J.
    Richardson, Paul
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (08) : 697 - 706
12345